Abstract CT150: Optimizing the therapeutic index of HDM2 inhibition: Results from a dose- and regimen-finding Phase I study of NVP-HDM201 in pts with TP53 wt advanced tumors
Year: 2017
Type: conference-abstract
Source: Cancer Research
Authors: David M. Hyman, Manik Chatterjee, Filip de Vos, Chia-Chi Lin, Cristina Suárez, David Tai, Philippe Cassier, Noboru Yamamoto, Vincent A. de Weger, Sébastien Jeay, Christophe Meille, Ensar Halilovic, Luisa Mariconti, Matthieu Klopfenstein, Nelson Guerreiro, Rajkumar Radhakrishnan, Emil T. Kuriakose, Sebastian Bauer
Institutions: Memorial Sloan Kettering Cancer Center, Universitätsklinikum Würzburg, University Medical Center Utrecht, National Taiwan University Hospital, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, National Cancer Centre Singapore, Centre Léon Bérard, The Netherlands Cancer Institute, Novartis (Switzerland), Novartis Institutes for BioMedical Research, Novartis (India), University of Duisburg-Essen
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2741097928